MXPA03001849A - Compuestos antitumorales triciclicos que son inhibidores de la farnesil proteino transferasa. - Google Patents

Compuestos antitumorales triciclicos que son inhibidores de la farnesil proteino transferasa.

Info

Publication number
MXPA03001849A
MXPA03001849A MXPA03001849A MXPA03001849A MXPA03001849A MX PA03001849 A MXPA03001849 A MX PA03001849A MX PA03001849 A MXPA03001849 A MX PA03001849A MX PA03001849 A MXPA03001849 A MX PA03001849A MX PA03001849 A MXPA03001849 A MX PA03001849A
Authority
MX
Mexico
Prior art keywords
protein transferase
transferase inhibitors
farnesyl protein
antitumor compounds
tricyclic
Prior art date
Application number
MXPA03001849A
Other languages
English (en)
Spanish (es)
Inventor
Ronald J Doll
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA03001849A publication Critical patent/MXPA03001849A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA03001849A 2000-08-30 2001-08-28 Compuestos antitumorales triciclicos que son inhibidores de la farnesil proteino transferasa. MXPA03001849A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22918300P 2000-08-30 2000-08-30
PCT/US2001/026792 WO2002018368A1 (en) 2000-08-30 2001-08-28 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors

Publications (1)

Publication Number Publication Date
MXPA03001849A true MXPA03001849A (es) 2003-06-04

Family

ID=22860141

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001849A MXPA03001849A (es) 2000-08-30 2001-08-28 Compuestos antitumorales triciclicos que son inhibidores de la farnesil proteino transferasa.

Country Status (27)

Country Link
US (1) US20020198216A1 (OSRAM)
EP (1) EP1313725B1 (OSRAM)
JP (1) JP2004513885A (OSRAM)
KR (1) KR20030034161A (OSRAM)
CN (1) CN100384837C (OSRAM)
AR (1) AR033680A1 (OSRAM)
AT (1) ATE359281T1 (OSRAM)
AU (2) AU8845101A (OSRAM)
BR (1) BR0113675A (OSRAM)
CA (1) CA2420673A1 (OSRAM)
CO (1) CO5640109A2 (OSRAM)
DE (1) DE60127846T2 (OSRAM)
EC (1) ECSP034494A (OSRAM)
ES (1) ES2284686T3 (OSRAM)
HK (1) HK1054548B (OSRAM)
HU (1) HUP0302942A3 (OSRAM)
IL (1) IL154528A0 (OSRAM)
MX (1) MXPA03001849A (OSRAM)
NO (1) NO20030918L (OSRAM)
NZ (1) NZ524246A (OSRAM)
PE (1) PE20020486A1 (OSRAM)
PL (1) PL361103A1 (OSRAM)
RU (1) RU2293734C9 (OSRAM)
SK (1) SK2292003A3 (OSRAM)
TW (1) TWI268280B (OSRAM)
WO (1) WO2002018368A1 (OSRAM)
ZA (1) ZA200301545B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
CA2440555A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
EP1435959A2 (en) * 2001-10-09 2004-07-14 University of Cincinnati Inhibitors of the egf receptor for the treatment of thyroid cancer
HUP0402401A2 (hu) * 2001-11-30 2005-03-29 Schering Corp. Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
CA2520172C (en) * 2003-03-27 2012-10-02 Lankenau Institute For Medical Research Novel methods for the treatment of cancer with an indoleamine 2, 3-dioxygenase inhibitor
WO2005000230A2 (en) * 2003-06-05 2005-01-06 Charles Achkar Methods of treating hyperproliferative cell disorders
WO2005001053A2 (en) * 2003-06-09 2005-01-06 Samuel Waksal Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
ES2235611B2 (es) * 2003-07-25 2006-07-16 Universidade De Santiago De Compostela Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas.
ATE417041T1 (de) * 2003-08-07 2008-12-15 Schering Corp Neue farnesylproteintransferaseinhibitoren als antitumormittel
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
AU2005319182A1 (en) * 2004-12-21 2006-06-29 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
RU2361587C1 (ru) * 2008-02-14 2009-07-20 Михаил Владимирович Кутушов Лекарственное средство для лечения онкологических заболеваний
WO2010006432A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
WO2020258211A1 (en) * 2019-06-28 2020-12-30 Anhui Ronghang Biotech Development Co., Ltd. Compositions and methods for treatment of hepatitis b virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
ZA914764B (en) * 1990-06-22 1992-03-25 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene,piperidylidene and piperazine compounds,compositions and methods of use
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
ATE293622T1 (de) * 1998-12-18 2005-05-15 Schering Corp Farnesyl protein transferase inhibitoren

Also Published As

Publication number Publication date
PE20020486A1 (es) 2002-06-14
AU2001288451C1 (en) 2008-03-06
NO20030918L (no) 2003-04-29
EP1313725B1 (en) 2007-04-11
CO5640109A2 (es) 2006-05-31
HUP0302942A3 (en) 2007-02-28
HK1054548A1 (en) 2003-12-05
JP2004513885A (ja) 2004-05-13
DE60127846T2 (de) 2008-03-06
DE60127846D1 (en) 2007-05-24
KR20030034161A (ko) 2003-05-01
EP1313725A1 (en) 2003-05-28
RU2293734C9 (ru) 2007-10-10
US20020198216A1 (en) 2002-12-26
AU2001288451B2 (en) 2007-05-24
SK2292003A3 (en) 2003-08-05
BR0113675A (pt) 2003-06-24
IL154528A0 (en) 2003-09-17
AU8845101A (en) 2002-03-13
PL361103A1 (en) 2004-09-20
CN100384837C (zh) 2008-04-30
NO20030918D0 (no) 2003-02-27
CN1471524A (zh) 2004-01-28
ATE359281T1 (de) 2007-05-15
TWI268280B (en) 2006-12-11
ES2284686T3 (es) 2007-11-16
ECSP034494A (es) 2003-04-25
CA2420673A1 (en) 2002-03-07
NZ524246A (en) 2004-11-26
HK1054548B (en) 2007-10-18
RU2293734C2 (ru) 2007-02-20
AR033680A1 (es) 2004-01-07
ZA200301545B (en) 2004-06-22
WO2002018368A1 (en) 2002-03-07
HUP0302942A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
AU2001240658A1 (en) Farnesyl protein transferase inhibitor combinations with camptothecin compounds
ZA200301545B (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors.
AU2001246477A1 (en) Farnesyl protein transferase inhibitor combinations with platinum compounds
AU2001254672A1 (en) Farnesyl protein transferase inhibitor combinations with an her2 antibody
ZA200206386B (en) Kinase inhibitors.
AU2001235496A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
PL348294A1 (en) Farnesyl protein transferase inhibitors
AU2001247882A1 (en) Tricyclic protein kinase inhibitors
AU2001239275A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
AU2001293835A1 (en) Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
PL357721A1 (en) Combination chemotherapy
IL123155A0 (en) 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
AU2001252147A1 (en) Farnesyl protein transferase inhibitor combinations
AU2001246478A1 (en) Farnesyl protein transferase inhibitor combinations with taxane compounds
AU2001244166A1 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
AU2001256166A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
AU2001253197A1 (en) Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
IL163673A0 (en) Farnesyl protein transferase inhibitors as antitumor agents
IL173514A0 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
AU2001244167A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
MXPA03002649A (es) Derivado de benzodiazepina.
NO20032471D0 (no) Farnesyltransferaseinhibitorer
IL143408A0 (en) Tricyclic farnesyl protein transferase inhibitors
AU2001242434A1 (en) Farnesyl protein transferase inhibitor combinations with vinca alkaloids
AU2435199A (en) Farnesyl transferase inhibitors

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration